Dopamine Synthesis Capacity and GABA and Glutamate Levels Separate Antipsychotic-Naïve Patients With First-Episode Psychosis From Healthy Control Subjects in a Multimodal Prediction Model.
18F-FDOPA PET
1HMRS
Antipsychotic-naïve
Dopamine
First-episode psychosis
GABA
Glx
schizophrenia
Journal
Biological psychiatry global open science
ISSN: 2667-1743
Titre abrégé: Biol Psychiatry Glob Open Sci
Pays: United States
ID NLM: 9918227369306676
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
31
01
2022
revised:
20
04
2022
accepted:
21
05
2022
medline:
30
5
2022
pubmed:
30
5
2022
entrez:
31
7
2023
Statut:
epublish
Résumé
Disturbances in presynaptic dopamine activity and levels of GABA (gamma-aminobutyric acid) and glutamate plus glutamine collectively may have a role in the pathophysiology of psychosis, although separately they are poor diagnostic markers. We tested whether these neurotransmitters in combination improve the distinction of antipsychotic-naïve patients with first-episode psychosis from healthy control subjects. We included 23 patients (mean age 22.3 years, 9 male) and 20 control subjects (mean age 22.4 years, 8 male). We determined dopamine metabolism in the nucleus accumbens and striatum from Individual neurotransmitters failed to predict group. Three triple neurotransmitter combinations significantly predicted group after Benjamini-Hochberg correction. The best model (Akaike information criterion 48.5) carried 93.5% of the cumulative model weight. It reached a classification accuracy of 83.7% ( Our multimodal approach proved superior classification accuracy, implying that the pathophysiology of patients represents a combination of neurotransmitter disturbances rather than aberrations in a single neurotransmitter. Particularly aberrant interrelations between K
Sections du résumé
Background
UNASSIGNED
Disturbances in presynaptic dopamine activity and levels of GABA (gamma-aminobutyric acid) and glutamate plus glutamine collectively may have a role in the pathophysiology of psychosis, although separately they are poor diagnostic markers. We tested whether these neurotransmitters in combination improve the distinction of antipsychotic-naïve patients with first-episode psychosis from healthy control subjects.
Methods
UNASSIGNED
We included 23 patients (mean age 22.3 years, 9 male) and 20 control subjects (mean age 22.4 years, 8 male). We determined dopamine metabolism in the nucleus accumbens and striatum from
Results
UNASSIGNED
Individual neurotransmitters failed to predict group. Three triple neurotransmitter combinations significantly predicted group after Benjamini-Hochberg correction. The best model (Akaike information criterion 48.5) carried 93.5% of the cumulative model weight. It reached a classification accuracy of 83.7% (
Conclusions
UNASSIGNED
Our multimodal approach proved superior classification accuracy, implying that the pathophysiology of patients represents a combination of neurotransmitter disturbances rather than aberrations in a single neurotransmitter. Particularly aberrant interrelations between K
Identifiants
pubmed: 37519478
doi: 10.1016/j.bpsgos.2022.05.004
pii: S2667-1743(22)00065-9
pmc: PMC10382695
doi:
Types de publication
Journal Article
Langues
eng
Pagination
500-509Subventions
Organisme : NICHD NIH HHS
ID : P50 HD103538
Pays : United States
Informations de copyright
© 2022 The Authors.
Références
Hum Brain Mapp. 2020 Apr 1;41(5):1119-1135
pubmed: 31737978
Schizophr Res. 2009 Mar;108(1-3):78-84
pubmed: 19056247
Stat Appl Genet Mol Biol. 2010;9:Article39
pubmed: 21044043
Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv105
pubmed: 26364273
Neuroscience. 2014 Dec 12;282:248-57
pubmed: 25445194
Shanghai Arch Psychiatry. 2015 Dec 25;27(6):341-7
pubmed: 27199525
Front Psychiatry. 2015 Nov 09;6:162
pubmed: 26617533
Nature. 2010 Apr 29;464(7293):1376-80
pubmed: 20393464
Neuropsychopharmacology. 2015 Jan;40(1):190-206
pubmed: 24759129
Front Psychiatry. 2016 Apr 08;7:52
pubmed: 27092086
Transl Psychiatry. 2021 Jun 17;11(1):367
pubmed: 34226485
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11651-4
pubmed: 7972118
Biol Psychiatry. 2022 Jan 15;91(2):170-172
pubmed: 34916029
Neuropharmacology. 2012 Mar;62(3):1574-83
pubmed: 21277876
Br J Psychiatry. 2011 Jun;198(6):448-56
pubmed: 21628707
Arch Gen Psychiatry. 2012 Dec;69(12):1195-204
pubmed: 22868877
Neuropsychopharmacology. 2020 Oct;45(11):1870-1876
pubmed: 32612207
Mol Psychiatry. 2016 Feb;21(2):198-204
pubmed: 25824298
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1480-3
pubmed: 20727934
Am J Psychiatry. 2002 Nov;159(11):1944-6
pubmed: 12411236
Biol Psychiatry. 2022 Jan 15;91(2):236-245
pubmed: 34743917
Biol Psychiatry. 2020 Feb 1;87(3):215-224
pubmed: 31561858
JAMA Psychiatry. 2021 Jun 1;78(6):667-681
pubmed: 33881460
Neural Plast. 2011;2011:723184
pubmed: 21904685
Neural Plast. 2016;2016:3915703
pubmed: 28003912
Psychol Med. 2019 Dec;49(16):2754-2763
pubmed: 30560750
Br J Psychiatry Suppl. 1998;172(33):14-20
pubmed: 9764121
J Neurosci. 2015 Jul 01;35(26):9615-21
pubmed: 26134644
Psychol Med. 2020 Jan;50(2):220-228
pubmed: 30642415
Arch Gen Psychiatry. 2004 Feb;61(2):134-42
pubmed: 14757589
Stereotact Funct Neurosurg. 2009;87(4):256-65
pubmed: 19556835
Schizophr Bull. 2020 Dec 1;46(6):1535-1546
pubmed: 32318717
Shanghai Arch Psychiatry. 2017 Oct 25;29(5):277-286
pubmed: 29276351
Neuroimage. 1999 Feb;9(2):179-94
pubmed: 9931268
Schizophr Bull. 2021 Mar 16;47(2):505-516
pubmed: 32910150
Trends Neurosci. 2011 Apr;34(4):188-97
pubmed: 21353710
Pharmacopsychiatry. 2006 Feb;39 Suppl 1:S10-4
pubmed: 16508890
Biol Psychiatry. 1999 Nov 15;46(10):1388-95
pubmed: 10578453
Schizophr Res. 2020 Dec;226:61-69
pubmed: 32723493
Psychon Bull Rev. 2004 Feb;11(1):192-6
pubmed: 15117008
Biol Psychiatry. 2010 Oct 1;68(7):667-70
pubmed: 20598290
Biol Psychiatry. 1999 Sep 1;46(5):681-8
pubmed: 10472420
Lancet. 1995 Oct 28;346(8983):1130-1
pubmed: 7475604
NPJ Schizophr. 2019 Aug 1;5(1):12
pubmed: 31371817
World J Biol Psychiatry. 2016 Jun;17(4):285-95
pubmed: 26453061
Schizophr Bull. 2013 Jan;39(1):33-42
pubmed: 22282454
Biol Psychiatry. 2018 Mar 15;83(6):475-483
pubmed: 29132653
J Neurosci. 2007 Jul 25;27(30):8080-7
pubmed: 17652599
Schizophr Bull. 2013 Sep;39(5):1096-104
pubmed: 23081992
Neuropsychopharmacology. 1988 Sep;1(3):179-86
pubmed: 3075131
Neuroimage Clin. 2014 Oct 15;6:398-407
pubmed: 25379453
Br J Psychiatry. 2007 Oct;191:325-34
pubmed: 17906243
Psychol Med. 2020 Oct;50(13):2182-2193
pubmed: 31524118
Schizophr Res. 2010 Mar;117(1):83-91
pubmed: 20022731
JAMA Psychiatry. 2017 Dec 1;74(12):1206-1213
pubmed: 29049482
Mol Psychiatry. 2021 Jun;26(6):2616-2625
pubmed: 32296127
Neuroimage Clin. 2021;32:102845
pubmed: 34662778
Neuropsychopharmacology. 2004 Nov;29(11):2052-64
pubmed: 15199377
Schizophr Res. 1997 Feb 7;23(2):167-74
pubmed: 9061812
Arch Gen Psychiatry. 2012 Aug;69(8):776-86
pubmed: 22474070
Biol Psychiatry. 2014 Mar 1;75(5):e11-3
pubmed: 23890739
Transl Psychiatry. 2020 Aug 10;10(1):276
pubmed: 32778656
Schizophr Res. 1999 Jan 4;35(1):41-50
pubmed: 9988840
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
Arch Gen Psychiatry. 1990 Jun;47(6):589-93
pubmed: 2190539
Annu Rev Neurosci. 1986;9:357-81
pubmed: 3085570
Arch Gen Psychiatry. 2012 May;69(5):449-59
pubmed: 22213769
Mol Psychiatry. 2021 Apr;26(4):1332-1345
pubmed: 31690805
Neuroimage. 1999 Feb;9(2):195-207
pubmed: 9931269
Neuroimage. 2012 Feb 1;59(3):3033-41
pubmed: 22036677
Mol Psychiatry. 2010 Jun;15(6):629-36
pubmed: 19918243
Schizophr Bull Open. 2021 Feb 02;2(1):sgaa072
pubmed: 34746793
Biol Psychiatry. 2021 Feb 1;89(3):278-287
pubmed: 32928500
Lancet Psychiatry. 2018 Oct;5(10):816-823
pubmed: 30236864
Mol Psychiatry. 2019 Oct;24(10):1502-1512
pubmed: 29679071
Hum Brain Mapp. 2009 Jan;30(1):112-21
pubmed: 18041743
Neuropsychopharmacology. 2021 May;46(6):1122-1132
pubmed: 32961543